At the end of the nomination period, nominated organisations will be jointly assessed by the GSK and Save the Children partnership on six broad criteria:
How is the product or practice truly innovative? Innovation is a match between a new solution and an unmet need that involves the creation and implementation of new processes, products, services and/or methods of delivery. To be considered successful, the innovation must:
- Be useful and significantly improve outcomes, efficiency, effectiveness and/or quality.
- Have delivered successful results in the two-year period preceding the nomination, ideally able to provide evidence of improved and/or increased access.
- Demonstrate the potential to be applied or replicated in other locations, and at an appropriate scale.
Even simple ideas applied in creative ways to overcome real-world challenges can be considered innovative. General/broad examples may include innovations that:
- Improve healthcare coverage, access, quality of care, or supply/demand dynamics.
- Improve behavioural change amongst practitioners, institutions, communities, or families.
- Improve government or other stakeholder capacity to identify and/or reduce the causes of under-5 child mortality (for example, through information, resources, services, capacities, or incentives).
How does the practice transform access and/or quality of care? A transformative innovation is one that will lead to beneficial change through pattern-breaking ideas that address at least one immediate or underlying cause of under-5 child mortality.
Where - country(s) and place(s) – is the innovation being trialled or implemented, and what is the extent (if any) to which the community and local government are using it?
What is the vision for the long-term impact of the innovation, and how will it be sustained in the future to create a lasting legacy?
How has the innovation been, or how can it be, applied or replicated in other locations, and how can it be brought to scale (if appropriate)? E.g. How can it be replicated at an appropriate scale, whether in similar circumstances or in a new environment? Has dialogue or partnerships been established to ensure that the innovation is transferable?
Award money application
How will the Award money be applied and what will the potential impact of the Award money be, in both the short and long term? How can the Award be used to improve, replicate and/or scale-up the innovation?